# TC BioPharm (TCBP) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/TCBP
## Company Profile
- Ticker: TCBP
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom and trades in the U
- Tags: Oncology
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
TC BioPharm is a cell-therapy biotechnology company focused on gamma delta T-cell approaches for cancer and related immune applications. Its story is built around a narrow platform that tries to create differentiated anti-cancer activity through engineered immune cells.
## Why The Stock Is Moving

Current closing-price context is not available for TCBP.

## Geographic Base

TC BioPharm is headquartered in the United Kingdom and trades in the U.S. market. It sits in cell therapy and oncology biotechnology.

## Business Model

The company depends on clinical progress, manufacturing feasibility, and access to capital to keep a narrow pipeline moving. Investors usually watch early data, safety, and platform validation.

## Landscape Position

TC BioPharm occupies a niche cell-therapy position within biotech. The stock is highly catalyst-sensitive because the company still needs to prove platform durability and clinical differentiation.

## Future Catalysts

- TC BioPharm’s catalysts are CAR-T / gamma-delta cell therapy updates and any strategic step that keeps the platform credible. The company still needs human proof.

## Recent News
- 2025-06-11 12:30 EST — [TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient](https://biopharmsignal.com/news/TCBP/tc-biopharm-announces-complete-response-in-minimal-residual-disease-mrd-patient) — Source: TC BioPharm
- 2025-04-09 13:00 EST — [TCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T Cells](https://biopharmsignal.com/news/TCBP/tcbp-announces-grant-of-european-patent-for-targeting-of-microbial-oncological-and-viral-indications-using-modified-gamma-delta-t-cells) — Source: TC BioPharm
- 2025-03-21 14:45 EST — [TCBP Announces Transition from Nasdaq to OTC Markets](https://biopharmsignal.com/news/TCBP/tcbp-announces-transition-from-nasdaq-to-otc-markets) — Source: TC BioPharm
- 2025-03-18 12:03 EST — [TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead](https://biopharmsignal.com/news/TCBP/tcbp-announces-outsourcing-initiatives-reducing-burn-rate-and-overhead) — Source: TC BioPharm
- 2025-03-05 13:30 EST — [TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company](https://biopharmsignal.com/news/TCBP/tcbp-announces-non-binding-letter-of-intent-to-acquire-commercial-stage-ophthalmic-pharmaceutical-company) — Source: TC BioPharm